Search DXCM
DEXCOM INC
Nasdaq · CIK 1093557
Last close85.36
Daily change-0.87 (-1.01%)
10 Years gain+301.79%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
DXCM · STANDARD
SIC 3841 · Surgical & Medical Instruments & Apparatus · Fiscal year end 1231
Fundamental
74.0Momentum
86.8Acceleration
86.8Confidence
85.0Annual Revenue17
Quarterly Revenue75
Annual CFO17
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth20.4 / 25
Quality14.8 / 25
Capital Efficiency20.0 / 20
Balance Sheet15.0 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
Gross margin expansionGross margin improved by 1.7017 percentage points.
Operating leverageOperating margin improved by 7.3643 percentage points.
Share count reductionDiluted share count declined 4.2699%.
Strong operating leverageOperating income is growing faster than revenue while operating margin expands.
Key Metrics
Revenue Growth TTM23.04%OK
Revenue CAGR 3Y17.01%OK
Gross Margin61.65%OK
Operating Margin21.14%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC120.62%OK
Incremental Operating Margin 3Y30.71%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y-4.27%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $4.66B | $2.80B | $911.80M | $1.44B | $1.08B | 60.1% | 19.56% | 23.11% | 87.86% | 405.5M |
| 2025 FY Dec 31, 2024 | $4.03B | $2.44B | $600.00M | $989.50M | $630.70M | 60.46% | 14.88% | 15.64% | n/a | 412.7M |
| 2025 FY Dec 31, 2023 | $3.62B | $2.29B | $597.70M | $748.50M | $511.90M | 63.19% | 16.5% | 14.13% | n/a | 425.5M |
| 2024 FY Dec 31, 2022 | $2.91B | $1.88B | $391.20M | $669.50M | $304.70M | 64.72% | 13.44% | 10.47% | n/a | 427.5M |
| 2023 FY Dec 31, 2021 | $2.45B | $1.68B | $265.80M | $442.50M | $53.30M | 68.63% | 10.86% | 2.18% | 123.42% | 428.8M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $4.87B | sum latest 4 fiscal quarters Revenue | OK | 0001093557-26-000143, 0001093557-25-000280 |
| Revenue Growth TTM | 23.04% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001093557-26-000143, 0001093557-25-000280 |
| Revenue CAGR 3Y | 17.01% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001093557-26-000027 |
| Revenue CAGR 5Y | 19.33% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001093557-26-000027 |
| Gross Profit CAGR 3Y | 14.16% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001093557-26-000027 |
| Operating Income Growth | 88.82% | OperatingIncome_current / OperatingIncome_prior_year - 1 | OK | 0001093557-26-000143, 0001093557-25-000280 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 61.65% | Gross Profit / Revenue | OK | 0001093557-26-000143, 0001093557-25-000280 |
| Operating Margin | 21.14% | Operating Income / Revenue | OK | 0001093557-26-000143, 0001093557-25-000280 |
| ROIC | 120.62% | NOPAT / Average Invested Capital | OK | 0001093557-26-000143, 0001093557-25-000280 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001093557-26-000143 |
| Current Ratio | 1.73x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $12.48 | Revenue / Diluted Shares | OK | 0001093557-26-000143, 0001093557-25-000280 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |